December 14, 2016 — Patients undergoing magnetic resonance (MR) exams will find a relaxing environment with Toshiba ...

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that target pivotal enzyme targets on cancer, announced a Phase I clinical trial has commenced in men with high-risk metastatic prostate cancer. In late August, the U.S. Food and Drug Administration cleared CTT’s first Investigational New Drug Application (IND) for a positron emission tomography (PET) imaging agent, CTT1057, labeled with a two-hour half life radiolabel, fluorine-18, and targeting prostate-specific membrane antigen (PSMA).

The American Society for Radiation Oncology (ASTRO) announced in November that Elekta has provided signficant financial support to RO-ILS: Radiation Oncology Incident Learning System a national patient safety initiative launched in 2014 by ASTRO and the American Association of Physicists in Medicine (AAPM). RO-ILS facilitates safer and higher quality care in radiation oncology by providing a mechanism for shared learning in a secure and non-punitive environment. It is the only medical specialty society-sponsored radiation oncology incident learning system within a federally listed Patient Safety Organization (PSO).

UCLA doctors have found what may be an earlier and easier way to diagnose chronic traumatic encephalopathy, or CTE, a disorder that is thought to affect some former football players and others with a history of repetitive brain trauma.

eRAD announced that it has successfully deployed its imaging workflow solutions, including RIS, PACS and Speech Recognition, at Open MRI of Connecticut.

Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be detected with their innovative diagnostic agent (Tc-99m duramycin-TumorVue) as early as one day after a single administration of drug.

In the largest-ever study on screening mammography outcomes, researchers found that there is no clear cut-off age to stop breast cancer screening. The findings was presented at the annual meeting of the Radiological Society of North America (RSNA).

Exact Imaging, a leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance of the prostate, announced it has received FDA 510(k) Clearance for its ExactVu micro-ultrasound system.